Use of autologous serum in ophthalmic practice;Aplicaciones del suero autólogo en oftalmología

Archivos de la Sociedad Espanola de Oftalmologia

Volumn 82, Issue 1, 2007, Pages 9-20

  Lopez Garcia J S ^a   Garcia Lozano I ^a,b   Rivas, L ^a,c   Martinez Garchitorena J ^a  

^a HOSPITAL CENTRAL DE LA CRUZ ROJA   (Spain)

^b Instituto de Ciencias Visuales (INCIVI)   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Autologous serum; Corneal epithelium; Dry eye; Impression cytology; Ocular surface

Indexed keywords

EYE DROPS;

BIOLOGICAL THERAPY; CORNEA DISEASE; HUMAN; PHYSIOLOGY; REVIEW; SERUM;

BIOLOGICAL THERAPY; CORNEAL DISEASES; HUMANS; OPHTHALMIC SOLUTIONS; SERUM;

EID: 34447509663     PISSN: 03656691     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 1984; 27: 459-461.
2. Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmolgy 1999; 106: 1984-1989.
3. Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, et al. Treatment of dry eye by autologous serum aplicattion in Sjogren's syndrome. Br J Ophthalmol 1999; 83: 390-395.
4. Tseng SC, Tsubota K. Important concepts for treating ocular surface and tear disorders. Am J Ophthalmol 1997; 124: 825-835.
5. Wilson SE, Liang Q, Kim WJ. Lacrimal gland HGF, KGF and EGF mRNA levels increase after corneal epithelial wounding. Invest Ophthalmol Vis Sci 1999; 40: 2185-2190.
6. Barton K, Nava A, Monroy DC, Pflugfelder SC. Cytokines and tear function in ocular surface disease. Adv Exp Med Biol 1998; 438: 461-469.
7. Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 2004; 88: 1467-1474.
8. Gobbels M, Spitznas M. Corneal epithelial permeability of dry eyes before and after treatment with artificial tears. Ophthalmology 1992; 99: 873-878.
9. Burstein NL. The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK 1985; 104: 402-409.
10. Geerling G, Sieg P, Meyer C, Bastian GO, Laqua H. Transplantation of autologous submandibular glands in very severe keratoconjunctivitis sicca. 2 year outcome. Ophthalmologe 1998; 95: 257-265.
11. Vajpayee RB, Mukerji N, Tandon R, Sharma N, Pandey RM, Biswas NR, et al. Evaluation of umbilical cord serum therapy for persistent corneal epithelial defects. Br J Ophthalmol 2003; 87: 1312-1316.
12. Borderie VM, Mourra N, Laroche L. Influence of fetal calf serum, fibroblast growth factors, and hepatocyte growth factor on three-dimensional cultures of human keratocytes in collagen gel matrix. Graefes Arch Clin Exp Ophthalmol 1999; 237: 861-869.
13. Kirschner SE. Persistent corneal ulcers. What to do when ulcers won't heal. Vet Clin North Am Small Anim Pract 1990; 20: 627-642.
14. Alvarado Valero MC, Martinez Toldos JJ, Borras Blasco J, Alminana Alminana A, Perez Ramos JM. Tratamiento de defectos epiteliales persistentes mediante suero autólogo. Arch Soc Esp Oftalmol 2004; 79: 537-542.
15. Kruse FE, Tseng SC. Serum differentially modulates the clonal growth and differentiation of cultured limbal and corneal epithelium. Invest Ophthalmol Vis Sci 1993; 34: 2976-2989.
16. van Setten GB, Tervo T, Tervo K, Tarkkanen A. Epidermal growth factor (EGF) in ocular fluids: presence, origin and therapeutical considerations. Acta Ophthalmol Suppl 1992; 202: 54-59.
17. Pastor JC, Calonge M. Epidermal growth factor and corneal wound healing. A multicenter study. Cornea 1992; 11: 311-314.
18. Collins MK, Perkins GR, Rodriguez-Tarduchy G, Nieto MA, Lopez-Rivas A. Growth factors as survival factors : regulation of apoptosis. Bioessays 1994; 16: 133-138.
19. Rodeck U, Jost M, Kari C, Shih DT, Lavker RM, Ewert DL, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110: 113-121.
20. Ohashi Y, Motokura M, Kinoshita Y, Mano T, Watanabe H, Kinoshita S, et al. Presence of epidermal growth factor in human tears. Invest Ophthalmol Vis Sci 1989; 30: 1879-1882.
21. Gupta A, Monroy D, Ji Z, Yoshino K, Huang A, Pflugfelder SC. Transforming growth factor beta-1 and beta-2 in human tear fluid. Curr Eye Res 1996; 15: 605-614.
22. Fredj-Reygrobellet D, Plouet J, Delayre T, Baudouin C, Bourret F, Lapalus P. Effects of aFGF and bFGF on wound healing in rabbit corneas. Curr Eye Res 1987; 6: 1205-1209.
23. Yoshino K, Garg R, Monroy D, Ji Z, Pflugfelder SC. Production and secretion of transforming growth factor beta (TGF-beta) by the human lacrimal gland. Curr Eye Res 1996; 15: 615-624.
24. Wilson SE, Lloyd SA, Kennedy RH. Basic fibroblast growth factor (FGFb) and epidermal growth factor (EGF) receptor messenger RNA production in human lacrimal gland. Invest Ophthalmol Vis Sci 1991; 32: 2816-2820.
25. Shimmura S, Ueno R, Matsumoto Y, Goto E, Higuchi A, Shimazaki J, et al. Albumin as a tear supplement in the treatment of severe dry eye. Br J Ophthalmol 2003; 87: 1279-1283.
26. Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol 2001; 85: 1188-1197.
27. Nishida T, Ohashi Y, Awata T, Manabe R. Fibronectin. A new therapy for corneal trophic ulcer. Arch Ophthalmol 1983; 101:1046-1048.
28. Phan TM, Foster CS, Shaw CD, Zagachin LM, Colvin RB. Topical fibronectin in an alkali burn model of corenal ulceration in rabbits. Arch Ophthalmol 1991; 109: 414-419.
29. Nishida T, Nakamura M, Ofuji K, Reid TW, Mannis MJ, Murphy CJ. Synergistic effects of substance P with insulin-like growth factor-1 on epithelial migration of the cornea. J Cell Physiol 1996; 169: 159-166.
30. Lagnado R, King AJ, Donald F, Dua HS. A protocol for low contamination risk of autologous serum drops in the management of ocular surface disorders. Br J Ophthalmol 2004; 88: 464-465.
31. Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, et al. Controlled study of the use of autologous serum in dry eye patients. Cornea 2001; 20: 802-806.
32. Malavazzi GR, Lake JC, Dantas PE. Effect of honey and autologous serum on corneal epithelial healing in rabbits. Arq Bras Oftalmol 2005; 68: 347-351.
33. Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynols A, Bridges LR, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004; 88: 647-652.
34. Pasternak AS, Miller WM. First-order toxicity assays for eye irritation using cell lines: parameters that affect in vitro evaluation. Fundam Appl Toxicol 1995; 25: 253-263.
35. Wang XM, Terasaki PI, Rankin GW jr, Chia D, Zhong HP, Haardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol 1993; 37: 264-270.
36. Geerling G, Daniels JT, Dart JK, Cree IA, Khaw PT. Toxicity of natural tear substitutes in a fully defined culture model of human corneal epithelial cells. Invest Ophthalmol Vis Sci 2001; 42: 948-956.
37. You L, Ebner S, Kruse FE. Glial cell-derived neurotrophic factor (GDNF)-induced migration and signal transduction in corneal epithelial cells. Invest Ophthalmol Vis Sci 2001; 42: 2496-2504.
38. Voak D, Cann R, Finney RD, Fraser ID, Mitchell R, Murphy MF, et al. Guidelines for administration of blood products: transfusion of infants and neonates. British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus Med 1994; 4: 63-69.
39. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G. An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol 2005; 243: 706-714.
40. Garcia Jimenez V, Veiga Villaverde B, Baamonde Arbaiza B, Cahue Carpintero I, Celemin Vinuela ML, Simo Martinez RM. The elaboration, use and evaluation of eye-drops with autologous serum in corneal lesions. Farm Hosp 2003; 27: 21-25.
41. Sitaramamma T, Shivaji S, Rao GN. Effect of storage on protein concentration of tear samples. Curr Eye Res 1998; 17: 1027-1035.
42. Mukerji N, Sinha R, Vajpayee RB. Role of autologous serum in persistent epithelial defects. Br J Ophthalmol 2002; 86: 832.
43. Sauer R, Bluthner K, Seitz B. Sterility of non-preserved autologous serum drops for treatment of persistent corneal epithelial defects. Ophthalmologe 2004; 101: 705-709.
44. Nakamura M, Nishida T, Mishima H, Otori T. Effects of antimicrobials on corneal epithelial migration. Curr Eye Res 1993; 12: 733-740.
45. Young AL, Cheng AC, Ng HK, Cheng LL, Leung GY, Lam DS. The use of autologuos serum tears in persistent corneal epithelial defects. Eye 2004; 18: 609-614.
46. Pfister RR. Clinical measures to promote corneal epithelial healing. Acta Ophthalmol Suppl 1992; 202: 73-83.
47. Ali Z, Insler MS. A comparison of therapeutic bandage lenses, tarsorrhaphy, and antibiotic and hypertonic saline on corneal epithelial wound healing. Ann Ophthalmol 1986; 18: 22-24.
48. Panda A, Pushker N, Bageshwar LM. Lateral tarsorrhaphy: is it preferable to patching? Cornea 1999; 18: 299-301.
49. Azuara-Blanco A, Pillai CT, Dua HS. Amniotic membrane transplantation for ocular surface reconstruction. Br J Ophthalmol 1999; 83: 399-402.
50. Tan DT, Ficker LA, Buckley RJ. Limbal transplantation. Ophthalmology 1996; 103: 29-36.
51. Gordon JF, Johnson P, Musch DC. Topical fibronectin ophthalmic solution in the treatment of persistent defects of the corneal epithelium. Chiron Vision Fibronectin Study Group. Am J Ophthalmol 1995; 119: 281-287.
52. Ralph RA. Tetracyclines and the treatment of corneal stromal ulceration: a review. Cornea 2000; 19: 274-277.
53. Pellegrini G, Traverso CE, Franzi AT, Zingirian M, Cancedda R, De Luca M. Long-term restoration of damaged corneal surfaces with autologous cultivated corneal epithelium. Lancet 1997; 349: 990-993.
54. Díaz-Valle D, Benítez del Castillo Sánchez JM, Díaz Rodríguez E, Toledano Fernández N, Arteaga Sánchez A, Sayagues Gómez O. Manejo de la queratopatía neurotrófica mediante tarsorrafia con cianoacrilato y suero autólogo. Arch Soc Esp Oftalmol 2003; 78: 119-122.
55. Matsumoto Y, Dogru M, Goto E, Ohashi Y, Kojima T, Ishida R, Tsubota K. Autologous serum application in the treatment of neurotrophic keratopathy. Ophthalmology 2004; 111: 1115-1120.
56. del Castillo JM, de la Casa JM, Sardina RC, Fernandez RM, Feijoo JG, Gomez AC, et al. Treatment of recurrent corneal erosions using autologous serum. Cornea 2002; 21: 781-783.
57. Tsubota K, Satake Y, Ohyama M, Toda I, Takano Y, Ono M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome. Am J Ophthalmol 1996; 122: 38-52.
58. Ogawa Y, Okamoto S, Mori T, Yamada M, Mashima Y, Watanabe R, et al. Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 2003; 31: 579-583.
59. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito AC, de Souza CA. GVDH dry eyes treated with autologous serum tears. Bone Marrow Transplant 2000; 25: 1101-1103.
60. Goto E, Shimmura S, Shimazaki J, Tsubota K. Treatment of superior limbic keratoconjunctivitis by application of autologous serum. Cornea 2001; 20: 807-810.
61. Matsuo H, Tomidokoro A, Tomita G, Araie M. Topical application of autologous serum for the treatment of late-onset aqueous oozing or point-leak through filtering bleb. Eye 2005; 19: 23-28.
62. Liggett PE, Skolik DS, Horio B, Saito Y, Alfaro V, Mieler W. Human autologous serum for the treatment of full-thickness macular holes. A preliminary study. Ophthalmology 1995; 102: 1071-1076.
63. Nakamura H, Hayakawa K, Sawaguchi S, Gaja T. Removal of retinal indocyanine green dye by autologous serum irrigation in macular hole surgery. Retina 2005; 25: 736-741.
64. Christmas NJ, Skolik SA, Howard MA, Saito Y, Barnstable CJ, Liggett PE. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology 1995; 102: 263-271.
65. Cullinane AB, O'Callaghan P, McDermott K, Keohane C, Cleary PE. Effects of autologous platelet concentrate and serum on retinal wound healing in an animal model. Graefes Arch Clin Exp Ophthalmol 2002; 240: 35-41.
66. McDonnell PJ, Schanzlin DJ, Rao NA. Immunoglobulin deposition in the cornea after application of autologous serum. Arch Ophthalmol 1988; 106: 1423-1425.
67. Eberle J, Habermann J, Gurtler LG. HIV-1 infection transmitted by serum droplets into the eye: a case report. AIDS 2000; 14: 206-207.
68. Yokoi N, Komuro A, Nishida K, Kinoshita S. Effectiveness of hyaluronan on corneal epithelial barrier function in dry eye. Br J Ophthalmol 1997; 81: 533-536.
69. Nelson JD, Drake MM, Brewer JT Jr, Tuley M. Evaluation of a physiological tear substitute in patients with keratoconjunctivitis sicca. Adv Exp Med Biol 1994; 350: 453-457.
70. Nelson JD, Gordon JF. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. Am J Ophthalmol 1992; 114: 441-447.